Dear Reader :

This month’s edition of Citeline’s newsletter, co-developed with the IPA, has a lot on the menu including the now and next pertaining to M&A in the US and opportunities in women’s health.

We bring you expert opinion on what the US FTC’s oversight of the Amgen/Horizon deal may mean for biopharma deal-making, while Ferring’s US CSO talks about the ‘vicious circle’ in women’s health investment.

Plus, there’s a fascinating piece on AI in cough diagnosis and management.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA
Perspective From Industry Leaders
Opportunities In Fertility: Recognizing Gaps In The Market Podcast: How Will Greater FTC Scrutiny Affect Biopharma M&A Activity?
Opportunities In Fertility: Recognizing Gaps In The Market Podcast: How Will Greater FTC Scrutiny Affect Biopharma M&A Activity?

Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where ...

Scrip’s Joseph Haas and Jessica Merrill discuss the US FTC’s oversight of the Amgen/Horizon deal and what ...
Licensing & Collaboration Agreements
Sandoz Fills Pipeline Gap With Samsung Bioepis’ Ustekinumab Fresenius And Formycon File Ustekinumab In Europe
Sandoz Fills Pipeline Gap With Samsung Bioepis’ Ustekinumab Fresenius And Formycon File Ustekinumab In Europe

Sandoz has filled a gap in its biosimilars pipeline by in-licensing Samsung Bioepis’ SB17 ustekinumab biosimilar to Stelara ...

Fresenius Kabi and Formycon have seen their filing for an ustekinumab biosimilar rival to Stelara accepted for review ...
Next Gen R&D
India's ImmunoACT Gears To Deliver CAR-T Therapy At Close To Transplant-Like Prices AI In Cough Diagnosis: Making A Vicious Cycle Virtuous
India's ImmunoACT Gears To Deliver CAR-T Therapy At Close To Transplant-Like Prices AI In Cough Diagnosis: Making A Vicious Cycle Virtuous

ImmunoACT gets go-ahead in India for its CD19-targeted CAR-T cell therapy, which reported low toxicity and the ...

Hyfe is extending AI to acoustics and championing technology it claims can transform the approach ...
Clinical Trials
Gene And Cell Therapy Clinical Holds Decline While Those For Drugs Hit 12-Year High The Clinical Trial Accessibility Checklist: How Does Your Organization Measure Up?
Gene And Cell Therapy Clinical Holds Decline While Those For Drugs Hit 12-Year High The Clinical Trial Accessibility Checklist: How Does Your Organization Measure Up?

FDA’s Center for Biologics Evaluation and Research saw IND clinical holds for gene and cell therapies dropped....

This year marks the 30th anniversary of the NIH revitalization act that required women and minorities to be...
Citeline Contact

Poornachandra Tejasvi .K,
Senior Director - Emerging Markets, India
Mobile: +91 9945273146
Email: poornachandra.tejasvi@citeline.com
Client Services: clientservices@citeline.com

alt_text   alt_text 		IPA Contact

Name: Hari Pranav K
Email: haripranav.k@ipa-india.org